FRIDAY, Sept. 27, 2024 (HealthDay News) -- An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a ...

As the researchers explained, a protein called TL1A appears to exacerbate ulcerative colitis, and tulisokibart is thought to work by mimicking the effect of natural antibodies that target TL1A ...

The trial details The trial that went on for 12 weeks involved two cohorts - all those with ulcerative colitis who had been taking steroids long-term or had failed other conventional and/or ...

Treatment for microscopic colitis aims to reduce these symptoms and help you achieve remission. Remission refers to a period where disease activity and symptoms improve or go away.

Colitis is an inflammation of the lining of the colon that can cause pain and discomfort. Learn more about the types, common symptoms and treatments available.

The drug, guselkumab, marketed under the brand name Tremfya, was approved Sept. 11, according to the release. The first dose was administered Sept. 17 to a 35-year-old man who has suffered from ...